Literature DB >> 25696581

Cardiac complications in type 2 diabetic patients with mild anginal symptoms and documented reversible myocardial perfusion defects: Results of the MERIDIAN trial.

J J Wiersma, L M Dijksman, W L Ten Holt, J M Radder, H J Verberne, B L F van Eck-Smit, M D Trip, T G V Cherpanath, P H J M Dunselman, J G P Tijssen, J J Piek.   

Abstract

BACKGROUND/
OBJECTIVE: To compare early invasive treatment with continued pharmacological treatment in patients with diabetes mellitus type 2, mild anginal symptoms and documented myocardial ischaemia.
METHODS: Patients with type 2 diabetes mellitus and mild anginal symptoms underwent myocardial perfusion scintigraphy (MPS). Patients with myocardial ischaemia were randomly assigned to early invasive or continued pharmacological treatment. All patients were followed for the occurrence of MACE (death, nonfatal myocardial infarction or hospitalisation for unstable angina pectoris).
RESULTS: A total of 156 patients were randomised when the sponsor (ZonMW) prematurely terminated the study because of a slow recruitment rate. With a mean follow-up of 2.1±0.6 years, 9 of 79 patients assigned to early invasive treatment developed MACE compared with 10 of 77 patients randomised to continued pharmacological treatment, annual event rate 5.4 vs. 6.3%, hazard ratio 0.89, 95% CI 0.36 to 2.20, p=0.34. Due to the limited number of included patients and the low event rate, the study did not have sufficient power for the study objective.
CONCLUSION: Patients with diabetes mellitus type 2, mild anginal symptoms and documented myocardial ischaemia, under appropriate medical treatment, have a lower than anticipated annual event rate of MACE of ±5 to 6% which questions the beneficial effect of early revascularisation.

Entities:  

Keywords:  angina pectoris; diabetes mellitus type 2; drug therapy; myocardial revascularisation; randomised controlled trials

Year:  2006        PMID: 25696581      PMCID: PMC2557327     

Source DB:  PubMed          Journal:  Neth Heart J        ISSN: 1568-5888            Impact factor:   2.380


  27 in total

1.  Long-term clinical outcome in the Bypass Angioplasty Revascularization Investigation Registry: comparison with the randomized trial. BARI Investigators.

Authors:  F Feit; M M Brooks; G Sopko; N M Keller; A Rosen; R Krone; P B Berger; R Shemin; M J Attubato; D O Williams; R Frye; K M Detre
Journal:  Circulation       Date:  2000-06-20       Impact factor: 29.690

Review 2.  Standardized myocardial segmentation and nomenclature for tomographic imaging of the heart. A statement for healthcare professionals from the Cardiac Imaging Committee of the Council on Clinical Cardiology of the American Heart Association.

Authors:  Manuel D Cerqueira; Neil J Weissman; Vasken Dilsizian; Alice K Jacobs; Sanjiv Kaul; Warren K Laskey; Dudley J Pennell; John A Rumberger; Thomas Ryan; Mario S Verani
Journal:  Circulation       Date:  2002-01-29       Impact factor: 29.690

3.  Asymptomatic Cardiac Ischemia Pilot (ACIP) study two-year follow-up: outcomes of patients randomized to initial strategies of medical therapy versus revascularization.

Authors:  R F Davies; A D Goldberg; S Forman; C J Pepine; G L Knatterud; N Geller; G Sopko; C Pratt; J Deanfield; C R Conti
Journal:  Circulation       Date:  1997-04-15       Impact factor: 29.690

4.  ACC/AHA 2002 guideline update for exercise testing: summary article: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee to Update the 1997 Exercise Testing Guidelines).

Authors:  Raymond J Gibbons; Gary J Balady; J Timothy Bricker; Bernard R Chaitman; Gerald F Fletcher; Victor F Froelicher; Daniel B Mark; Ben D McCallister; Aryan N Mooss; Michael G O'Reilly; William L Winters; Raymond J Gibbons; Elliott M Antman; Joseph S Alpert; David P Faxon; Valentin Fuster; Gabriel Gregoratos; Loren F Hiratzka; Alice K Jacobs; Richard O Russell; Sidney C Smith
Journal:  Circulation       Date:  2002-10-01       Impact factor: 29.690

5.  Secondary prevention of cardiovascular events with long-term pravastatin in patients with diabetes or impaired fasting glucose: results from the LIPID trial.

Authors:  Anthony Keech; David Colquhoun; James Best; Adrienne Kirby; R John Simes; David Hunt; Wendy Hague; Elaine Beller; Manjula Arulchelvam; Jennifer Baker; Andrew Tonkin
Journal:  Diabetes Care       Date:  2003-10       Impact factor: 19.112

6.  Global burden of diabetes, 1995-2025: prevalence, numerical estimates, and projections.

Authors:  H King; R E Aubert; W H Herman
Journal:  Diabetes Care       Date:  1998-09       Impact factor: 19.112

7.  Cause-specific mortality in a population-based study of diabetes.

Authors:  S E Moss; R Klein; B E Klein
Journal:  Am J Public Health       Date:  1991-09       Impact factor: 9.308

8.  A comparison of angioplasty with medical therapy in the treatment of single-vessel coronary artery disease. Veterans Affairs ACME Investigators.

Authors:  A F Parisi; E D Folland; P Hartigan
Journal:  N Engl J Med       Date:  1992-01-02       Impact factor: 91.245

9.  Explaining the decline in coronary heart disease mortality in England and Wales between 1981 and 2000.

Authors:  Belgin Unal; Julia Alison Critchley; Simon Capewell
Journal:  Circulation       Date:  2004-03-01       Impact factor: 29.690

10.  Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction.

Authors:  S M Haffner; S Lehto; T Rönnemaa; K Pyörälä; M Laakso
Journal:  N Engl J Med       Date:  1998-07-23       Impact factor: 91.245

View more
  2 in total

1.  Risk stratification in diabetic patients: a continuing challenge.

Authors:  Todd D Miller; Leslee J Shaw
Journal:  J Nucl Cardiol       Date:  2009-06-18       Impact factor: 5.952

Review 2.  Clinical usefulness of novel serum and imaging biomarkers in risk stratification of patients with stable angina.

Authors:  George Tsaknis; Iraklis Tsangaris; Ignatios Ikonomidis; Argirios Tsantes
Journal:  Dis Markers       Date:  2014-06-19       Impact factor: 3.434

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.